Determinants of New Product Launch Success in the Pharmaceutical Industry
暂无分享,去创建一个
[1] Iain Black. Marketing Masterclass — Pharmaceutical marketing strategy: Lessons from the medical literature , 2005 .
[2] Andy Powrie-Smith,et al. European Federation of Pharmaceutical Industries and Associations , 2017 .
[3] S. Wold,et al. The Collinearity Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses , 1984 .
[4] Dhruv Grewal,et al. Evaluation of subsidiary marketing performance: combining process and outcome performance metrics , 2007 .
[5] Jürg J. Hari,et al. The relevance of marketing activities in the Swiss prescription drugs market: Two empirical qualitative studies , 2009 .
[6] J. Edward Jackson,et al. A User's Guide to Principal Components: Jackson/User's Guide to Principal Components , 2004 .
[7] Gregory S. Carpenter,et al. Measuring Marketing Productivity: Current Knowledge and Future Directions , 2004 .
[8] Erik Jan Hultink,et al. The Impact of the Corporate Mind‐set on New Product Launch Strategy and Market Performance , 2010 .
[9] Roger J. Calantone,et al. Clustering product launches by price and launch strategy , 2007 .
[10] Stephen Scypinski. Editorial: Speed and Efficiency in Pharmaceutical Development , 2009, Journal of Pharmaceutical Innovation.
[11] Foo-Tim Chau,et al. Recipe for uncovering the bioactive components in herbal medicine. , 2009, Analytical chemistry.
[12] Glenn B. Voss,et al. Strategic Orientation and Firm Performance in an Artistic Environment , 2000 .
[13] John C. Narver,et al. The Effect of a Market Orientation on Business Profitability , 1990 .
[14] B. Smith. An Exploratory Study of Key Opinion Leadership Management Trends among European Pharmaceutical Companies , 2009 .
[15] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[16] Nils-Olof Lindberg,et al. Multivariate methods in pharmaceutical applications , 2002 .
[17] K. Zhou,et al. The Effects of Strategic Orientations on Technology- and Market-Based Breakthrough Innovations , 2005 .
[18] J. DiMasi,et al. Drug development costs when financial risk is measured using the Fama-French three-factor model. , 2009, Health economics.
[19] A. Griffin,et al. PDMA Success Measurement Project: Recommended Measures for Product Development Success and Failure , 1996 .
[20] Erik Jan Hultink,et al. Managing diffusion barriers when launching new products , 2010 .
[21] Johan A Westerhuis,et al. A systematic approach to obtain validated partial least square models for predicting lipoprotein subclasses from serum NMR spectra. , 2014, Analytical chemistry.
[22] J. Edward Jackson,et al. A User's Guide to Principal Components. , 1991 .
[23] Todd J. Arnold,et al. Achieving relationship marketing effectiveness in business-to-business exchanges , 2008 .
[24] Christian Homburg,et al. A Multiple-Layer Model of Market-Oriented Organizational Culture: Measurement Issues and Performance Outcomes , 2000 .
[25] O. Kvalheim,et al. Biomarker discovery in mass spectral profiles by means of selectivity ratio plot , 2009 .
[26] O. Kvalheim,et al. A multivariate approach to reveal biomarker signatures for disease classification: application to mass spectral profiles of cerebrospinal fluid from patients with multiple sclerosis. , 2010, Journal of proteome research.
[27] Dennis A. Pitta,et al. New product introduction at TyRx Pharma, Inc. , 2006 .
[28] Dennis Z. Kvesic,et al. Product Lifecycle Management: Marketing Strategies for the Pharmaceutical Industry , 2008 .
[29] Subhash Sharma,et al. The Role of Relational Information Processes and Technology Use in Customer Relationship Management , 2005 .
[30] Liam Fahey,et al. The resource-based view and marketing: The role of market-based assets in gaining competitive advantage , 2001 .
[31] G. Day. Managing market relationships , 2000 .
[32] Nicholas J. Ashill,et al. Pharmaceutical marketing return‐on‐investment: a European perspective , 2007 .
[33] Jayashree Dubey,et al. Pharmaceutical innovation and generic challenge: recent trends and causal factors , 2010 .
[34] R. Calantone,et al. Determinants of New Product Performance: A Review and Meta-Analysis , 1994 .
[35] Basil Achilladelis,et al. The dynamics of technological innovation : the case of the pharmaceutical industry , 2001 .
[36] W. J. Lundstrom,et al. Physicians' Perceptions of Pharmaceutical Sales Representatives: A Model for Analysing the Customer Relationship , 2004 .
[37] Sean McGrath. Market access – An essential investment before drug launch , 2010 .
[38] S. Hunt,et al. The Commitment-Trust Theory of Relationship Marketing , 1994 .
[39] John C. Narver,et al. Responsive and proactive market orientation and new-product success. , 2004 .
[40] E. Rogers,et al. Diffusion of innovations , 1964, Encyclopedia of Sport Management.
[41] Michel Rod,et al. The informative and persuasive components of pharmaceutical promotion , 2009 .
[42] Peter R.J. Trim,et al. A new product launch strategy (NPLS) model for pharmaceutical companies , 2005 .
[43] Dieter Scharitzer,et al. Satisfied customers: Profitable customer relationships: Pharmaceutical marketing: How pharmaceutical sales representatives can achieve economic success through relationship management with settled general practitioners—an empirical study , 2000 .
[44] Fred Langerak,et al. An Appraisal of Research on the Predictive Power of Market Orientation , 2003 .
[45] Tasadduq A. Shervani,et al. Market-Based Assets and Shareholder Value: A Framework for Analysis , 1998 .
[46] A. Griffin,et al. An Interim Report on Measuring Product Development Success and Failure , 1993 .
[47] Abbie Griffin,et al. Industrial New Product Launch Strategies and Product Development Performance , 1997 .
[48] Geoffrey A. Moore. Crossing the chasm : marketing and selling high-tech products to mainstream customers , 1999 .
[49] Nic S. Terblanche. New pharmaceutical product development: Barriers to overcome and opportunities to exploit , 2008 .
[50] Tarja Rajalahti,et al. Discriminating variable test and selectivity ratio plot: quantitative tools for interpretation and variable (biomarker) selection in complex spectral or chromatographic profiles. , 2009, Analytical chemistry.
[51] Aleksandar Ruzicic,et al. Marketing Masterclass: Salesforce Effectiveness: Is the Pharmaceutical Industry going in the Right Direction?: , 2007 .
[52] Gerard A. Athaide,et al. The Determinants of Seller‐Buyer Interactions during New Product Development in Technology‐Based Industrial Markets , 2011 .
[53] C. Benedetto,et al. Identifying the key success factors in new product launch , 1999 .
[54] E. V. van Raaij,et al. The Implementation of a Market Orientation: A Review and Integration of the Contributions to Date , 2008 .
[55] Ernst R Berndt,et al. An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts. , 2002, The journal of mental health policy and economics.
[56] E. Hultink,et al. The Impact of Market Orientation, Product Advantage, and Launch Proficiency on New Product Performance and Organizational Performance , 2004 .
[57] Manish Gupta,et al. Application of Multivariate Tools in Pharmaceutical Product Development to Bridge Risk Assessment to Continuous Verification in a Quality by Design Environment , 2010, Journal of Pharmaceutical Innovation.
[58] R Bro,et al. Cross-validation of component models: A critical look at current methods , 2008, Analytical and bioanalytical chemistry.
[59] J. DiMasi. The Value of Improving the Productivity of the Drug Development Process , 2012, PharmacoEconomics.
[60] Vittorio Chiesa,et al. Commercializing Technological Innovation: Learning from Failures in High-Tech Markets* , 2011 .
[61] Angela Paladino,et al. Investigating the Drivers of Innovation and New Product Success: A Comparison of Strategic Orientations* , 2007 .
[62] Francesco Savorani,et al. Effect of trans Fatty Acid Intake on LC-MS and NMR Plasma Profiles , 2013, PloS one.
[63] Birgitta Sandberg. Creating the market for disruptive innovation: Market proactiveness at the launch stage , 2002 .
[64] Ira Horowitz,et al. New-product success in the pharmaceutical industry: how many bites at the cherry? , 2005 .
[65] Abbie Griffin,et al. Launch decisions and new product success: an empirical comparison of consumer and industrial products , 2000 .
[66] J. DiMasi,et al. Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009 , 2011, Clinical pharmacology and therapeutics.
[67] Olav M. Kvalheim,et al. Interpretation of latent-variable regression models , 1989 .
[68] K. Möller,et al. Relationship Marketing Theory: Its Roots and Direction , 2000 .
[69] A. Benedetto,et al. Strategic orientations and new product commercialization : mediator, moderator, and interplay , 2011 .
[70] Age K. Smilde,et al. Variable importance in latent variable regression models , 2014 .
[71] O. Kvalheim,et al. Multivariate data analysis in pharmaceutics: a tutorial review. , 2011, International journal of pharmaceutics.
[72] C. Benedetto. Identifying the key success factors in new product launch , 1999 .
[73] Ulrike de Brentani,et al. Performance of Global New Product Development Programs: A Resource‐Based View , 2007 .
[74] Rasmus Bro,et al. Variable selection in regression—a tutorial , 2010 .
[75] G. Odekerken-Schröder,et al. Investments in Consumer Relationships: A Cross-Country and Cross-Industry Exploration , 2001 .
[76] Ahmet H. Kirca,et al. Market Orientation: A Meta-Analytic Review and Assessment of its Antecedents and Impact on Performance , 2005 .
[77] Nick Lee,et al. Marketing dimensions in the prescription pharmaceutical industry: a systematic literature review , 2015 .